http://www.pranabio.com/


PBT434 is Prana’s lead drug under development for Parkinson’s disease, Parkinsonian syndromes, and other movement disorders. The drug has completed the first stage of preclinical toxicology studies, with the support of The Michael J Fox Foundation, and is now completing further toxicology studies to be ready to start Phase 1 clinical trials at the end of 2014.

“PBT434 has proven effective in preventing neuronal loss and preserving motor function in three different animal models of Parkinson’s disease. PBT434 also inhibits the accumulation of alpha synuclein, a hallmark of the disease, which is promoted by increasing iron levels in the brain. Elevation of iron in the brain is a well-established pathological feature of Parkinson’s disease,” said Associate Professor Cherny, Prana’s Head of Research on the Study,